Clinical Trial Update: Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients [Phase 3]

View source ↗

Summary

A Phase 3 pharmacokinetics study of a maraviroc and boosted atazanavir dual regimen in stable HIV-infected patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)
• atazanavir boosted regimen (atazanavir boosted regimen)

Snippet

Sponsor: University of Turin, Italy | Conditions: HIV Infection | Phase 3 | Status: WITHDRAWN